Use of platelet-rich plasma for COVID-19-related olfactory loss: a randomized controlled trial

Carol H Yan, Sophie S Jang, Hung-Fu C Lin, Yifei Ma, Ashoke R Khanwalkar, Anthony Thai, Zara M Patel, Carol H Yan, Sophie S Jang, Hung-Fu C Lin, Yifei Ma, Ashoke R Khanwalkar, Anthony Thai, Zara M Patel

Abstract

Introduction: The current study evaluated the use of platelet-rich plasma (PRP), an autologous blood product with supraphysiologic concentrations of growth factors, in the treatment of prolonged coronavirus disease 2019 (COVID-19)-related smell loss.

Methods: This multi-institutional, randomized controlled trial recruited patients with COVID-19 who had objectively measured smell loss (University of Pennsylvania Smell Identification Test [UPSIT] ≤ 33) between 6 and 12 months. Patients were randomized to three intranasal injections of either PRP or sterile saline into their olfactory clefts. The primary outcome measure was change in Sniffin' Sticks score (threshold, discrimination, and identification [TDI]) from baseline. The secondary end point measures included responder rate (achievement of a clinically significant improvement, ≥5.5 points TDI), change in individual TDI olfaction scores, and change in subjective olfaction via a visual analog scale.

Results: A total of 35 patients were recruited and 26 completed the study. PRP treatment resulted in a 3.67-point (95% CI: 0.05-7.29, p = 0.047) greater improvement in olfaction compared with the placebo group at 3 months and a higher response rate (57.1% vs 8.3%, odds ratio 12.5 [95% exact bootstrap confidence interval, 2.2-116.7]). There was a greater improvement in smell discrimination following PRP treatment compared with placebo but no difference in smell identification or threshold. There was no difference in subjective scores between PRP and placebo. No adverse effects were reported.

Conclusion: Olfactory function following COVID-19 can improve spontaneously after 6 months and can improve to a greater extent with PRP injection. These data build on the promise of PRP to be a safe potential treatment option for patients with COVID-19-related smell loss, and larger-powered studies will help further assess its efficacy.

Keywords: COVID-19; PRP; anosmia; long COVID; olfaction; persistent olfactory dysfunction; platelet-rich plasma; post COVID syndrome; smell loss; therapeutics.

© 2022 ARS-AAOA, LLC.

Figures

FIGURE 1
FIGURE 1
CONSORT (Consolidated Standards of Reporting of Observational Studies) flow diagram of the study recruitment and analysis. COVID, coronavirus disease 2019; PRP, platelet‐rich plasma.
FIGURE 2
FIGURE 2
Measured psychophysical (threshold, discrimination, identification [TDI]) and subjective (visual analog scale [VAS]) olfaction scores at baseline and 1 month and 3 months after treatment, from linear mixed models adjusted for baseline score. Error bars represent 95% confidence intervals (CIs).

References

    1. Tan BKJ, Han R, Zhao JJ, et al. Prognosis and persistence of smell and taste dysfunction in patients with covid‐19: meta‐analysis with parametric cure modelling of recovery curves. BMJ. 2022;378:e069503.
    1. Patel ZM, Holbrook EH, Turner JH, et al. International consensus statement on allergy and rhinology: olfaction. Int Forum Allergy Rhinol. 2022;12(4):327‐680.
    1. Said M, Luong T, Jang SS, Davis ME, DeConde AS, Yan CH. Clinical factors associated with lower health scores in COVID‐19–related persistent olfactory dysfunction. Int Forum Allergy Rhinol. 2022;12(10):1242‐1253.
    1. Burges Watson DL, Campbell M, Hopkins C, Smith B, Kelly C, Deary V. Altered smell and taste: anosmia, parosmia and the impact of long Covid‐19. PLoS One. 2021;16(9):e0256998.
    1. Vaira LA, Gessa C, Deiana G, et al. The effects of persistent olfactory and gustatory dysfunctions on quality of life in long‐COVID‐19 patients. Life. 2022;12(2):141.
    1. Webster KE, O'Byrne L, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction. Cochrane Database Syst Rev. 2022;9(9):CD013877.
    1. Patel ZM, Wise SK, DelGaudio JM. Randomized controlled trial demonstrating cost‐effective method of olfactory training in clinical practice: essential oils at uncontrolled concentration. Laryngoscope Investig Otolaryngol. 2017;2(2):53‐56.
    1. Damm M, Pikart LK, Reimann H, et al. Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter study. Laryngoscope. 2014;124(4):826‐831.
    1. Lechner M, Liu J, Counsell N, et al. The COVANOS trial – insight into post‐COVID olfactory dysfunction and the role of smell training. Rhin. 2022;60(3):188‐199.
    1. Yaylacı A, Azak E, Önal A, Aktürk DR, Karadenizli A. Effects of classical olfactory training in patients with COVID‐19‐related persistent loss of smell. Eur Arch Otorhinolaryngol. 2022;Jul 29:1‐7.
    1. Pires Íde AT, Steffens ST, Mocelin AG, et al. Intensive olfactory training in post‐COVID‐19 patients: a multicenter randomized clinical trial. Am J Rhinol Allergy. 2022:36(6):780‐787.
    1. Nguyen TP, Patel ZM. Budesonide irrigation with olfactory training improves outcomes compared with olfactory training alone in patients with olfactory loss. Int Forum Allergy Rhinol. 2018;8(9):977‐981.
    1. Gupta S, Lee JJ, Perrin A, et al. Efficacy and safety of saline nasal irrigation plus theophylline for treatment of COVID‐19‐related olfactory dysfunction: the SCENT2 Phase 2 randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2022;148(9):830‐837.
    1. Kasiri H, Rouhani N, Salehifar E, Ghazaeian M, Fallah S. Mometasone furoate nasal spray in the treatment of patients with COVID‐19 olfactory dysfunction: a randomized, double blind clinical trial. Int Immunopharmacol. 2021;98:107871.
    1. Yan CH, Rathor A, Krook K, et al. Effect of omega‐3 supplementation in patients with smell dysfunction following endoscopic sellar and parasellar tumor resection: a multicenter prospective randomized controlled trial. Neurosurgery. 2020;87(2):E91‐E98.
    1. Vaira LA, Hopkins C, Petrocelli M, et al. Efficacy of corticosteroid therapy in the treatment of long‐ lasting olfactory disorders in COVID‐19 patients. Rhin. 2021;59(1):21‐25.
    1. Di Stadio A, D'Ascanio L, Vaira LA, et al. Ultramicronized palmitoylethanolamide and luteolin supplement combined with olfactory training to treat post‐COVID‐19 olfactory impairment: a multi‐center double‐blinded randomized placebo‐controlled clinical trial. CN. 2022:20(10):2001‐2012.
    1. Lerner D, Garvey K, Arrighi‐Allisan A, et al. Letter to the editor: study summary ‐ randomized control trial of omega‐3 fatty acid supplementation for the treatment of COVID‐19 related olfactory dysfunction. Trials. 2020;21(1):942.
    1. Wang S, Liu X, Wang Y. Evaluation of platelet‐rich plasma therapy for peripheral nerve regeneration: a critical review of literature. Front Bioeng Biotechnol. 2022;10:808248.
    1. Yan CH, Mundy DC, Patel ZM. The use of platelet‐rich plasma in treatment of olfactory dysfunction: a pilot study. Laryngoscope Investig Otolary. 2020;5(2):187‐193.
    1. Mavrogeni P, Kanakopoulos A, Maihoub S, Krasznai M, Szirmai A. Anosmia treatment by platelet rich plasma injection. Int Tinnitus J. 2017;20(2):102‐105.
    1. Steffens Y, Le Bon SD, Lechien J, et al. Effectiveness and safety of PRP on persistent olfactory dysfunction related to COVID‐19. Eur Arch Otorhinolaryngol. 2022:279(12):5951‐5953.
    1. Yasak AG, Yigit O, Araz Server E, Durna Dastan S, Gul M. The effectiveness of platelet‐rich plasma in an anosmia‐induced mice model. Laryngoscope. 2018;128(5):E157‐E162.
    1. Khan AM, Lee J, Rammaha T, et al. Natural trajectory of recovery of COVID‐19 associated olfactory loss. Am J Otolaryngol. 2022;43(5):103572.
    1. London B, Nabet B, Fisher AR, White B, Sammel MD, Doty RL. Predictors of prognosis in patients with olfactory disturbance. Ann Neurol. 2008;63(2):159‐166.
    1. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. ‘Sniffin’ sticks’: olfactory performance assessed by the combined testing of odour identification, odor discrimination and olfactory threshold. Chem Senses. 1997;22(1):39‐52.
    1. Parzen M, Lipsitz S, Ibrahim J, Klar N. An estimate of the odds ratio that always exists. J Comput Graph Statist. 2002;11(2):420‐436.
    1. Tutar B, Ekincioglu E, Karaketir S, et al. The impact of platelet‐rich fibrin (PRF) on olfactory function and pain after septoplasty operations. Eur Arch Otorhinolaryngol. 2020;277(4):1115‐1120.
    1. Goljanian Tabrizi A, Asadi M, Mohammadi M, Abedi Yekta A, Sohrabi M. Efficacy of platelet‐rich plasma as an adjuvant therapy to endoscopic sinus surgery in anosmia patients with sinonasal polyposis: a randomized controlled clinical trial. Med J Islam Republ Iran. 2021;35:156.
    1. Prajapati DP, Shahrvini B, Said M, Srinivas S, DeConde AS, Yan CH. Assessment of patient recognition of coronavirus disease 2019 (COVID‐19)‐associated olfactory loss and recovery: a longitudinal study. Int Forum Allergy Rhinol. 2021;11(11):1529‐1537.
    1. Holbrook EH, Rebeiz L, Schwob JE. Office‐based olfactory mucosa biopsies. Int Forum Allergy Rhinol. 2016;6(6):646‐653.
    1. Amable PR, Carias RBV, Teixeira MVT, et al. Platelet‐rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013;4(3):67.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe